- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02983396
The Accuracy of the Mini RELF Device for the Diagnosis of an Acute Coronary Artery Occlusion. (RELF IIa)
The Accuracy of the Mini RELF Device Relative to the 12 Lead ECG for the Diagnosis of an Acute Coronary Artery Occlusion in Patients With Coronary Artery Disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The increasing availability of small hand held medical devices is a novel opportunity to develop a tool that guides patients through the decision-taking processes of seeking medical attendance during symptoms suggestive of acute myocardial infarction. The cornerstone of early diagnosis, risk stratification and treatment is the presence of ST segment elevation during symptoms suggestive of STEMI. Therefore, a hand held medical device that can detect ST segment elevation with high sensitivity and specificity could be a breakthrough in the further reduction of fatality from acute myocardial infarction. A number of conditions of the tool must be fulfilled to allow save use with a low threshold in the general population. Most important is the accuracy to detect any new ST segment elevation related to an acute artery occlusion. For more than 30 years the 12-lead ECG is the gold standard for detection of ST elevation. However, acute coronary occlusions of a posterior or lateral segment are not always detected by the gold standard. Moreover, in the very early phase of acute coronary occlusion, the accuracy 12 lead ECG is inadequate.
In a previous study "Diagnostic accuracy of a novel method for detection of acute transmural myocardial ischemia based upon a self-applicable 3-lead configuration" the investigators developed and validated a sensitive and specific 3-lead ECG method (RELF method). The method includes a new lead configuration and a new algorithm to analyze the ECG recordings based on an intra-individual comparisons of ST levels. In summary, a 3-lead recording from a healthy subject or from a patient with an acute coronary occlusion is compared automatically to one or more previous reference recordings from the same individual. The individualized ST shift is used as a decision variable to detect or reject an acute coronary artery occlusion. The RELF method was more accurate then the simultaneously applied 12-lead ECG which had a lower sensitivity and specificity. In that study all recordings were performed by a sophisticated ECG recording system. The RELF method is designed to be applicable also by small hand held ECG devices such as the self-applicable Mini RELF device.
In the current study the investigators aim to evaluate the accuracy of Mini RELF device relative to the 12 lead ECG when the device is self-applied on a daily basis by patients with coronary artery disease. In a parallel study (RELF IIb) the investigators aim to evaluate the specificity of the RELF method when it is self-applied by healthy subjects who are representative for future users of the device.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brugge, Belgium, 8000
- Algemeen Ziekenhuis Sint-Jan Brugge
-
Ghent, Belgium, 9000
- University Hospital Ghent
-
Sint-Niklaas, Belgium, 9100
- AZ Sint Nikolaas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who have an appointment for an elective coronary angioplasty.
Exclusion Criteria:
- Patients with coronary artery bypass grafts.
- Patients with implanted pacemaker or ICD.
- Patients who remain hospitalized until the planned angioplasty.
- Patient who are unfamiliar with use of smart phone. The test question "did you use by yourself a smart phone to make a telephone call in the last 4 weeks" should be answered by yes.
- Patients who cannot tolerate repetitive applications of standard skin electrodes on the chest.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: no transmural ischemia (NTI) and transmural ischemia (TI)
Case cross-over from "no transmural ischemia (NTI)" to "transmural ischemia at 60 s coronary occlusion during elective coronary angioplasty (TI)" Comparison of diagnostic accuracy of standard 12-lead ECG versus Mini RELF device for detection of transmural ischemia. |
Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The accuracy (Area under the sensitivity-aspecificity curve) of Modus RELF-2 (The orthonormalized ST shift vector magnitude)
Time Frame: One week after coronary angioplasty
|
The sensitivity and specificity of the orthonormalized ST shift vector magnitude during occlusion compared to the sensitivity and specificity of the 12 lead ECG.
|
One week after coronary angioplasty
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The accuracy (Area under the sensitivity-aspecificity curve) of Modus RELF-3
Time Frame: One week after coronary angioplasty
|
The sensitivity and specificity of the intraindividual orthonormalized ST shift vector magnitude
|
One week after coronary angioplasty
|
|
The accuracy (Area under the sensitivity-aspecificity curve) of Modus RELF-1 (The gender specific orthonormalized ST vector magnitude) and of Modus RELF-3 (The intra-individual orthonormalized ST shift vector magnitude).
Time Frame: One week after coronary angioplasty
|
The sensitivity and specificity of the gender specific orthonormalized ST vector magnitude and the intra-individual orthonormalized ST shift vector magnitude during occlusion compared to the sensitivity and specificity of the 12 lead ECG.
|
One week after coronary angioplasty
|
|
Number of participants with symptoms of contact dermatitis in the thoracic device-skin contact area.
Time Frame: One week after coronary angioplasty
|
Contact dermatitis is defined by the clinical presence of redness or itching or blistering delineated in the thoracic device-skin contact area during at least one of the three clinical visits in the study participation period.
|
One week after coronary angioplasty
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Peter Gheeraert, Professor, University Ghent, Belgium
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UniversityGhent
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ST Elevation Myocardial Infarction
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationCompletedST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionUnited States, Spain, Netherlands, Canada, Australia, Serbia, Egypt, Switzerland, Hungary, United Kingdom, France, Czechia, Nepal, North Macedonia
-
Inha University HospitalCompletedST Segment Elevation Myocardial Infarction | Non-ST Segment Elevation Myocardial InfarctionKorea, Republic of
-
Chinese PLA General HospitalCompletedST Elevation (STEMI) Myocardial InfarctionChina
-
RenJi HospitalCompletedST Segment Elevation Myocardial Infarction
-
Dong-A UniversityTerminatedST-Segment Elevation Myocardial InfarctionKorea, Republic of
-
Azienda Ospedaliera San Camillo ForlaniniUnknownST Segment Elevation Myocardial InfarctionItaly
Clinical Trials on Diagnostic accuracy of Mini Relf Device
-
Federal University of São PauloCompletedCarpal Tunnel Syndrome | Compression Neuropathy, Carpal Tunnel | Median Neuropathy, Carpal TunnelBrazil
-
IRCCS Burlo GarofoloCompleted
-
Second Xiangya Hospital of Central South UniversityThe First Affiliated Hospital with Nanjing Medical University; Sun Yat-Sen... and other collaboratorsRecruitingDiabetes Mellitus Type 2 | Diabetes Mellitus ComplicationsChina
-
University Hospital, BordeauxRecruitingPremature Baby 26 to 32 Weeks | Premature Baby 33 to 36 WeeksFrance
-
University Hospital, BordeauxCompletedCirculatory Failure (Shock)France
-
Melbourne HealthRecruitingVital Signs | Inpatients | Hospital-at-homeAustralia
-
Marmara University Pendik Training and Research...CompletedHeart Diseases | Heart Failure | Acute Heart FailureTurkey
-
Foundation for Innovative New Diagnostics, SwitzerlandUniversidad Peruana Cayetano Heredia; Kenya Medical Research Institute; V. N.... and other collaboratorsActive, not recruitingTuberculosis, Multidrug-ResistantZambia, Peru, Ukraine, Kenya, Moldova
-
BayerCompletedHypertension, PulmonaryFrance, South Korea